Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice*

The peroxisome proliferator-activated receptor alpha (PPARα) activator fenofibrate efficiently decreases plasma triglycerides (TG), which is generally attributed to enhanced very low density lipoprotein (VLDL)-TG clearance and decreased VLDL-TG production. However, because data on the effect of fenofibrate on VLDL production are controversial, we aimed to investigate in (more) detail the mechanism underlying the TG-lowering effect by studying VLDL-TG production and clearance using APOE*3-Leiden.CETP mice, a unique mouse model for human-like lipoprotein metabolism. Male mice were fed a Western-type diet for 4 weeks, followed by the same diet without or with fenofibrate (30 mg/kg bodyweight/day) for 4 weeks. Fenofibrate strongly lowered plasma cholesterol (−38%) and TG (−60%) caused by reduction of VLDL. Fenofibrate markedly accelerated VLDL-TG clearance, as judged from a reduced plasma half-life of glycerol tri[3H]oleate-labeled VLDL-like emulsion particles (−68%). This was associated with an increased post-heparin lipoprotein lipase (LPL) activity (+110%) and an increased uptake of VLDL-derived fatty acids by skeletal muscle, white adipose tissue, and liver. Concomitantly, fenofibrate markedly increased the VLDL-TG production rate (+73%) but not the VLDL-apolipoprotein B (apoB) production rate. Kinetic studies using [3H]palmitic acid showed that fenofibrate increased VLDL-TG production by equally increasing incorporation of re-esterified plasma fatty acids and liver TG into VLDL, which was supported by hepatic gene expression profiling data. We conclude that fenofibrate decreases plasma TG by enhancing LPL-mediated VLDL-TG clearance, which results in a compensatory increase in VLDL-TG production by the liver.

[1]  B. S. Mohammed,et al.  Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  C. Mayer,et al.  NuGO contributions to GenePattern , 2008, Genes & Nutrition.

[3]  J. Jukema,et al.  Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[4]  J. Jukema,et al.  Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. , 2008, Atherosclerosis.

[5]  Y. Deshaies,et al.  Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. , 2008, Metabolism: clinical and experimental.

[6]  J. Jukema,et al.  Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007. , 2007, Journal of Lipid Research.

[7]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[8]  S. Kersten,et al.  PPARα and dyslipidemia , 2007 .

[9]  J. Jukema,et al.  Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[10]  G. Watts,et al.  Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. , 2006, Clinical science.

[11]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[12]  N. Maeda,et al.  Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. , 2006, Journal of hepatology.

[13]  Somesh D. Sharma,et al.  Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice , 2006, Molecular and Cellular Biochemistry.

[14]  A. Häkkinen,et al.  Overproduction of large VLDL particles is driven by increased liver fat content in man , 2006, Diabetologia.

[15]  Daniel J. Vis,et al.  T-profiler: scoring the activity of predefined groups of genes using gene expression data , 2005, Nucleic Acids Res..

[16]  B. Teusink,et al.  Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. , 2005, Journal of lipid research.

[17]  L. Havekes,et al.  Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400301-JLR200 , 2005, Journal of Lipid Research.

[18]  U. Edvardsson,et al.  Activation of Peroxisome Proliferator-activated Receptor α Increases the Expression and Activity of Microsomal Triglyceride Transfer Protein in the Liver* , 2005, Journal of Biological Chemistry.

[19]  M. Chapman.  Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. , 2003, Atherosclerosis.

[20]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Watts,et al.  Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.

[22]  B. Teusink,et al.  Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. , 2003, Diabetes.

[23]  J. Borén,et al.  Influence of Peroxisome Proliferator-activated Receptor α Agonists on the Intracellular Turnover and Secretion of Apolipoprotein (Apo) B-100 and ApoB-48* , 2002, The Journal of Biological Chemistry.

[24]  E. Fisher,et al.  Complexity in the Secretory Pathway: The Assembly and Secretion of Apolipoprotein B-containing Lipoproteins* , 2002, The Journal of Biological Chemistry.

[25]  J. Oscarsson,et al.  PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins. , 2001, Journal of lipid research.

[26]  C. Semenkovich,et al.  PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. , 2001, The Journal of clinical investigation.

[27]  W. Boden.  High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. , 2000, The American journal of cardiology.

[28]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[29]  J. Peters,et al.  Altered Constitutive Expression of Fatty Acid-metabolizing Enzymes in Mice Lacking the Peroxisome Proliferator-activated Receptor α (PPARα)* , 1998, The Journal of Biological Chemistry.

[30]  T. V. van Berkel,et al.  Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. , 1997, Journal of lipid research.

[31]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[32]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[33]  E. Bruckert,et al.  Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[34]  J. Auwerx,et al.  Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.

[35]  M. Hanefeld,et al.  Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. , 1995, Biochimica et biophysica acta.

[36]  D. Moore,et al.  The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.

[38]  R. G. Lamb,et al.  An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. , 1993, Biochimica et biophysica acta.

[39]  Henry N. Ginsberg,et al.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. , 1992, The Journal of clinical investigation.

[40]  A. Tall,et al.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. , 1992, The Journal of clinical investigation.

[41]  D. Goldberg,et al.  Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. , 1992, Biochemical pharmacology.

[42]  R. Zechner,et al.  Rapid and simple isolation procedure for lipoprotein lipase from human milk. , 1990, Biochimica et biophysica acta.

[43]  L. de Roy,et al.  Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. , 1989, Atherosclerosis.

[44]  S. Grundy,et al.  Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. , 1983, Journal of lipid research.

[45]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[46]  C. Harvengt,et al.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects , 2004, European Journal of Clinical Pharmacology.

[47]  S. Grundy,et al.  Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins. , 1996, Journal of lipid research.